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Increased sympathetic activity is important in the pathogenesis of hypertension and insulin resistance. Afferent signaling from the
kidneys elevates the central sympathetic drive. We investigated the effect of catheter-based renal sympathetic denervation (RDN)
on glucose metabolism, inflammatory markers, and blood pressure in nondiabetic patients with treatment-resistant hypertension.
Eight subjects were included in an open-labelled study. Each patient was studied before and 6 months after RDN. Endogenous
glucose production was assessed by a 3-3H glucose tracer, insulin sensitivity was examined by hyperinsulinemic euglycemic
clamp, hormones and inflammatory markers were analyzed, and blood pressure was measured by office blood pressure readings
and 24-hour ambulatory blood pressure monitoring. Insulin sensitivity (M-value) increased nonsignificantly from 2.68± 0.28 to
3.07± 0.41 (p = 0 12). A significant inverse correlation between the increase in M-value and BMI 6 months after RDN (p = 0 03)
was found, suggesting beneficial effects on leaner subjects. Blood pressure decreased significantly, but there were no changes in
hormones, inflammatory markers, or endogenous glucose production. Our results indicate that RDN may improve insulin
sensitivity in some patients with treatment-resistant hypertension, albeit confirmation of these indications of beneficial effects
on leaner subjects awaits the outcome of larger randomized controlled studies.
1. Introduction
Hypertension is associated with impaired glucose metabo-
lism and insulin resistance [1], and an increased central sym-
pathetic activity plays an important role in both conditions.
Afferent signaling from the kidneys is an important contrib-
utor to the elevated central sympathetic drive, leading to
hypertension, insulin resistance, heart failure, and potentially
chronic kidney disease [2]. Despite the availability of many
safe and effective antihypertensive drugs, blood pressure in
many patients remains poorly controlled and there has been
an increasing interest in the use of catheter-based renal
denervation (RDN) to treat resistant hypertension [3]. The
clinical results on RDN for the treatment of resistant
hypertension are however diverse [3–6]. The overall effect
of RDN on blood pressure is questionable, but it seems
that there might be responders and nonresponders. Further
studies have also been suggested to assess the effectiveness
of RDN treatment for heart failure, insulin resistance,
obstructive sleep apnea, atrial fibrillation, and end-stage
renal disease [3]. In the current study, we investigated the
effect of RDN on glucose metabolism, using gold standard
methods, that is, hyperinsulinemic euglycemic clamp
(HEC) and glucose isotope dilution, to assess hepatic and
peripheral insulin sensitivity. As increased inflammation
is associated with both hypertension and insulin resistance
[7, 8], we also evaluated the effect of RDN on inflamma-
tory markers. Accordingly, our study was designed to test
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whether an attenuation of the sympathetic nervous system
by RDN would improve both insulin sensitivity and blood
pressure and reduce inflammation.
2. Material and Methods
2.1. Study Participants. Eight patients with treatment-
resistant hypertension (6 males and 2 females), defined as
daytime 24-hour ambulatory blood pressure monitoring
(ABPM) systolic blood pressure≥ 145mmHg (preceded by
1 month of scheduled drug intake showing at least 85%
adherence), were included in the study. The inclusion criteria
for treatment-resistant hypertension did not strictly follow
AHA guidelines, as the patients in the current study were
recruited from the Reset Study [9]. The study criteria are
presented in Table 1. The participants were healthy, except
for having treatment-resistant hypertension, as assessed by
self-report, previous medical history, a physical examination,
and a broad biochemical profile. Secondary forms of hyper-
tension were excluded by means of computed axial tomogra-
phy (CT) imaging of renal arteries, echocardiography, and
hormone analysis. Prior to the inclusion of the current study,
the 8 subjects had participated in the Reset Study [9] as part
of the sham group, ensuring that drug intake was sufficient
the preceding 6 months before inclusion in our study.
The participants were asked to fill in a questionnaire at
baseline and at follow-up 6 months after RDN, concerning
medical history, medication, smoking habits, physical activ-
ity, diet, and sleeping patterns, and they were asked not to
implement changes in lifestyle during the intervention
period. Changes in antihypertensive medication during
follow-up were only allowed if requested by the patient or if
potentially harmful changes in blood pressure arose. Study
subjects were told to refrain from major physical exercise
48 hours prior to both study days.
The participants gave a written informed consent prior
to the study participation. The study was conducted in
accordance with the Helsinki Declaration, and the study
protocol was reviewed and approved by the Regional Ethical
Committee. The protocol was registered at Clinicaltrials.gov.
NCT01631370.
2.2. Design. The study was open-labelled, where each patient
was studied on two occasions, shortly before RDN and 6
months after RDN.
On the day of the study, the subjects rested on bed from
0730 h in a quiet, thermoneutral environment. The subjects
fasted from the night before and during the experiments.
An intravenous cannula was inserted into an antecubital vein
for infusions, and another intravenous cannula was inserted
into a dorsal hand vein for blood sampling. The latter was
maintained heated, allowing for arterialized blood samples
to be drawn. Plasma glucose levels were determined every
10min during the clamp period, and blood samples were
drawn at t = 0, 100, 110, 120, 220, 230, and 240min.
At first, a 2-hour basal period (t = 0–120min) was per-
formed with infusion of a 3-3H glucose tracer to assess
endogenous glucose production. The basal period was
followed by a 2-hour clamp period (t = 120–240min) with
Table 1: Study criteria.
Inclusion
(i) Age 30 to 70 years
(ii) One month of stable antihypertensive treatment with at least
three antihypertensive agents including a diuretic (or in case
of diuretic intolerance, a minimum of three nondiuretic
antihypertensive drugs)
(iii) Daytime ABPM systolic blood pressure≥ 145mmHg
(preceded by 1 month of scheduled drug intake showing at
least 85% adherence)
Exclusion
General
(i) Noncompliant personality (abuse, mental illness)
(ii) Pregnancy/inadequate contraception in fertile women
(iii) Known allergy to iodine-containing X-ray contrast agent
Comorbidity
(i) Diabetes
(ii) Secondary hypertension
(iii) Malignant disease
(iv) Congestive heart failure NYHA 3-4
(v) Chronic renal failure stages 4-5 (eGFR≤ 30ml/min/1.73m2)
(vi) Stable angina pectoris (CCS classes 2–4)
(vii) Unstable angina pectoris
(viii) Coronary artery disease with indication for coronary
intervention
(ix) Recent myocardial infarction or coronary intervention
(<6 months)
(x) Permanent atrial fibrillation
(xi) Orthostatic syncope (<6 months)
(xii) Symptomatic peripheral artery disease
Paraclinical
(i) Clinically significant abnormal electrolytes and liver function
tests.
(ii) Hemoglobin< 7.0mmol/l
(iii) Abnormal thyroid function
(iv) Macroscopic haematuria
(v) ECG: AV-block grades 2 and 3 or AV-block grades 1 + branch
block
Echocardiography
(i) Left ventricular ejection fraction< 50%
(ii) Significant valvular disease
CT-angiography and selective angiography of renal arteries
(i) Pronounced calcification in iliaco-aortic or renal arteries
(ii) Multiple renal arteries: accessory renal arteries estimated to
carry more than 10% of the kidney’s blood supply (small polar
arteries accepted) and being undersized (see below) for abla-
tion procedure
(iii) Renal artery diameter< 4mm
(iv) Renal artery length (from ostium to first major side
branch)< 20mm
(v) Renal artery disease (stenosis, fibromuscular dysplasia; prior
intervention, dissection)
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a HEC to assess insulin sensitivity. The 3-3H glucose tracer
infusion continued during the clamp period. Indirect calo-
rimetry was performed during the last 30 minutes of both
the basal period and the clamp period.
2.3. Blood Pressure Measurements. Office blood pressure
readings were taken in a seated position 30 minutes after
the end of the study day. Averages of the triplicate measures
were used. ABPM was done using either the SpaceLab 90207
or 90217 ABPM monitor with BP readings every 20 minutes.
Nighttime and daytime periods were defined as 23:00–07:00
(night) and 07:00–23:00 (day). Aminimum of 50% successful
readings during nighttime and daytime was demanded for
each ABPM to qualify for analysis.
2.4. Hyperinsulinemic Euglycemic Clamp. The HEC was
performed to assess insulin sensitivity. Insulin (Actrapid;
Novo Nordisk, Bagsværd, Denmark) was given from
t = 120min as a continuous infusion at 0.8mU× kg−1×min−1
for 120 minutes. Insulin infusates were prepared in 19ml
of isotonic saline and 1ml of the subject’s blood to pre-
vent adsorption of insulin to plastic surfaces and infused
at 5ml/hour. Plasma glucose was clamped at 5mmol/l by
adjusting the infusion rate of 20% glucose according to
plasma glucose measurements. Plasma glucose was measured
every 10min immediately after sampling. Glucose was given
with a carrier infusion of 0.9% NaCl. To prevent hypoka-
lemia, 0.22meq/l KCl was added the glucose infusate.
Steady-state plasma glucose infusion rates during the last
30 minutes of the clamp were used for estimating insulin
sensitivity (M-value) [10, 11].
2.5. Tracer. For the assessment of endogenous glucose pro-
duction (EGP) during both the basal and the clamp
period, the 3-3H glucose tracer (New England Nuclear Life
Science Products, Boston, MA, USA) was infused from
t = 0–40min (0.12 μCi/min). A priming dose of 3-3H glucose
(12 μCi) was given as a bolus of 1.5ml prior to the constant
infusion [12]. The tracer (3–3 H glucose) was added to the
glucose infusion during the clamp period. Glucose flux
rates were calculated at 10min intervals from t = 100–120
and t = 220–240min [13]. Glucose rate of appearance (Ra)
was calculated from Steele’s equation for a nonsteady state
[14, 15]. During the clamp period, EGP was calculated by
subtracting the rate of exogenous glucose infusion from the
rate of appearance of 3–3H glucose.
2.6. Indirect Calorimetry. The respiratory quotient (RQ) and
resting energy expenditure (REE) were estimated by indirect
calorimetry using a computerized flow through a canopy gas
analyzer system (Deltatrac; Datex Instruments, Helsinki,
Finland). Indirect calorimetry was performed during the last
30 minutes of the basal period and during the last 30 minutes
of the clamp period. Mean values of the last 25min were used
for calculations. Lipid oxidation and glucose oxidation were
estimated after correction for protein oxidation, which were
calculated on the basis of urea nitrogen excretion [16].
2.7. Blood Analyses and Assays. Plasma levels of creatinine,
electrolytes, lipids, HbA1c, TSH, and liver enzymes were
determined by standard laboratory measures. Plasma glu-
cose was measured in duplicate immediately after sampling
on Beckman Glucoanalyzers (Beckman Instruments, Palo
Alto, CA). Serum and EDTA plasma samples were frozen
immediately after collection and stored at −20°C until the
time of analyses.
The specific activity of 3-3H glucose was measured as
described [17]. Insulin (DAKO, Glostrup, Denmark), C-
peptide (ALPCO, Salem, NH, USA), and cortisol (EIA-
1887, AH-Diagnostic) were analyzed using ELISA-based kits.
Free fatty acids (FFA) were analyzed with a commercial kit
(Wako Chemicals, Neuss, Germany). Plasma cytokines
(interleukin- (IL-) 1β, IL6, IL-10, IFN-γ, and TNF-α) were
analyzed by Luminex Performance Human High Sensitivity
Cytokine Magnetic Panel A (Bio-Techne, Abingdon, UK).
Detection limit for the analytes was between 0.3 and 1.5 pg/
ml. High-sensitive C-reactive protein (hsCRP, BAM 17072,
and MAB 17071, R&D Systems Europe Ltd., Abingdon,
UK) was analyzed using an in-house assay. Adiponectin
was analyzed by a validated in-house time-resolved immu-
nofluorometric assay (TRIFMA) as previously described
[18]. The detection limit was 1.5 μg/l, and intra- and
interassay coefficients of variation were <5% and <7%,
respectively. Glucagon was analyzed by an in-house radioim-
munoassay [19]. Total IGF-I was measured in acid ethanol-
extracted serum, using an in-house TRIFMA as previously
described [20].
2.8. Renal Denervation. RDN was carried out at one single
invasive cardiovascular center and performed by one single
experienced invasive cardiologist with a record of 45 proce-
dures before initiating the current protocol. Patients were
admitted in the morning and prepared for femoral artery
catheterization with a 6F diagnostic catheter. Pretreatment
included oral acetaminophen and 10mg oral morphine.
Unless previously examined, a coronary angiography was
performed at first, in order to exclude possible asymptomatic
severe proximal coronary stenosis. Thereafter, renal angi-
ography was performed to confirm the findings from the
renal CT angiography that renal artery anatomy was suit-
able for RDN therapy (Table 1). At this moment, sedation
was administered (fentanyl, midazolam) and the Symplicity
renal denervation catheter (Medtronic) was advanced, and
four-to-six discrete, low-power radio frequency treatments
were applied circumferentially along the length of each main
renal artery, aiming at covering the entire lumen. After the
procedure, patients were submitted to the ward for routine
observation and were discharged in the evening or the
next morning.
2.9. Safety. All adverse events and complication were system-
atically recorded. Specific interventional-related safety data
included bleeding or femoral pseudoaneurysm requiring
intervention, renal artery dissection, myocardial infarction,
stroke, and death. Specific follow-up-related safety record
concerned blood pressure, renal function, electrolyte disar-
rangement, stroke, transitory ischemic attack, myocardial
infarction, and symptomatic hypotension.
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2.10. Statistical Analysis. Results are expressed as mean± SE
(parametric data) or median (range) (nonparametric data).
Data were tested for normal distribution using the Shapiro-
Wilk test. Differences between baseline and endpoint mea-
sures and between basal and clamp data were assessed using
a one-sample t-test or Wilcoxon signed-rank test, as appro-
priate. A p value <0.05 was considered statistically significant.
Pearson correlation was used to test for correlations. Power
calculations were based on the primary endpoint, namely,
M-values, and a detectable difference in M-values was 14%.
It could be calculated that eight patients would be required
to demonstrate a significant difference at 80% power and
5% significance. All calculations were carried out using Sigma
Plot version 11.0.
3. Results
3.1. Patient Characteristics and Medication. Clinical charac-
teristics of the study subjects are presented in Table 2. Six
men and 2 postmenopausal women were included. Subjects
were nondiabetic with a HbA1C at 37.0 (35.0; 39.0) mmol/
mol. There were no significant changes in BMI, HbA1c, fast-
ing plasma glucose, or lipid profile before and 6 months after
renal denervation. There were no changes in prescription
during the six-month follow-up. Medication for cardiovascu-
lar disease and hypertension comprised the following: ace
inhibitor (n = 2), angiotensin receptor blocker (n = 6), cal-
cium channel blocker (n = 7), beta blocker (n = 3), thiazide
diuretic (n = 3), aldosterone inhibitor (n = 1), alpha adren-
ergic blocker (n = 4), centrally acting sympatholytic agent
(n = 1), acetylsalicylic acid (n = 5), and lipid-lowering
treatment (n = 2).
3.2. Insulin Sensitivity, Endogenous Glucose Production,
and Hormones. Insulin sensitivity expressed as M-value
improved nonsignificantly from 2.68± 0.28 to 3.07
± 0.41 mg/kg/min (p = 0 12) (Figure 1). However, a signifi-
cant inverse correlation between the increase in M-value
and BMI 6 months after RDN (p = 0 03) (Figure 2) was
found. EGP decreased insignificantly both during the basal
period (1.73± 0.16 versus 1.36± 0.19 mg/kg/min (p = 0 27))
and during the clamp period (0.62± 0.14 versus 0.36
± 0.28 mg/kg/min (p = 0 52)) 6 months after RDN. There
were no significant changes in C-peptide, glucagon, free
Table 2: Anthropometric and biochemical measures.
Characteristics Baseline 6 months after RDN p value
Men/women 6/2
Age (years) 62.5± 2.55
BMI (kg/m2) 28.9 (26.6; 34.0) 29.9 (26.4; 34.2) 0.94
Fasting plasma glucose (mmol/l) 6.31± 0.35 6.14± 0.31 0.29
HbA1c (mmol/mol) 37.0 (35.0; 39.0) 37.5 (36.0; 40.5) 0.58
P-sodium (mmol/l) 142.4± 0.68 141.9± 0.74 0.52
P-potassium (mmol/l) 3.45 (3.15; 3.60) 3.55 (3.40; 3.65) 0.06
P-total cholesterol (mmol/l) 5.26± 0.41 5.25± 0.36 0.91
P-LDL cholesterol (mmol/l) 3.18± 0.34 3.19± 0.31 0.94
P-HDL cholesterol (mmol/l) 1.33± 0.11 1.34± 0.14 0.74
P-triglycerides (mmol/l) 1.45 (1.05; 2.25) 1.35 (1.10; 1.95) 0.94
P-TSH (×10−3 ie/l) 1.95 (1.36; 2.81) 1.80 (1.40; 2.73) 0.38
P-ALAT (I/U) 23.50± 3.82 23.63± 4.83 0.93
P-creatinine (μmol/l) 86.88± 7.52 84.38± 7.62 0.53
eGFR (ml/min) 72.38± 4.80 76.00± 4.67 0.31
B-leucocytes (×109/l) 5.36± 0.39 5.49± 0.46 0.76
B-thrombocytes (×109/l) 194.4± 15.9 188.1± 14.6 0.40
B-hemoglobin (mmol/l) 9.04± 0.26 8.93± 0.24 0.41
All data are presented as means with SE or median (range).
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Figure 1: M-values for the 8 subjects at baseline and at 6 months
after RDN. Two subjects have the same M-values and cannot be
separated from each other in the graph (from 2.4 to 2.0 after 6
months). The thick black line depicts mean values of the M-values
(2.86 versus 3.07; p = 0 12).
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fatty acids (FFA), insulin, cortisol, or IGF-I after 6 months
(Table 3).
3.3. Systemic Inflammation. Interferon-γ, IL-1β, IL-6, IL-10,
and TNF-α were analyzed, but as cytokine levels were very
low, only IL-1β, IL-6, and TNF-α were detectable and were
not affected significantly 6 months after RDN (Table 3).
3.4. Energy Expenditure. Fasting and insulin-stimulated rest-
ing energy expenditure (EE) and respiratory quotient (RQ)
were obtained by indirect calorimetry and did not change sig-
nificantly 6 months after RDN. Glucose oxidation, however,
decreased significantly (p = 0 018) during the clamp period
after RDN. Concurrently, lipid oxidation increased the bor-
derline significantly (p = 0 06), whereas protein oxidation
was practically unchanged (Table 3).
3.5. Blood Pressure Data. Six months after RDN, office
systolic blood pressure and office diastolic blood pressure
decreased significantly from 180.4± 6.79 to 164± 8.06
(p = 0 01) and 94.88± 4.72 to 87.88± 3.63 (p = 0 04), respec-
tively. There were a significant borderline decrease in
nighttime ABPM systolic blood pressure (p = 0 06) and a
significant decrease in nighttime ABPM diastolic blood
pressure (p = 0 03) (Table 4).
4. Discussion
This study, based on a small sample size, showed no overall
effect of RDN on insulin sensitivity, assessed by the HEC.
The significant inverse correlation between the increase in
M-value and BMI 6 months after RDN could indicate that
RDN could have a potential effect on nonobese subjects,
without severe insulin resistance. This is in a way a puzzling
finding as obesity contributes to an increase in sympathetic
nervous system activity and obesity itself contributes to insu-
lin resistance. However, one could speculate that the most
obese subjects in the current study are so insulin resistant
due to their obesity that the renal denervation is relatively less
effective compared to the leaner subjects that are less insulin
resistant. Our findings are in line with the recently published
study by Miroslawka et al. [21] where 23 patients with
treatment-resistant hypertension underwent RDN and a
two-step HEC with glucose tracer infusion was performed
before and 6 months after RDN. The authors found no
improvement in insulin sensitivity, but 18 subjects had the
metabolic syndrome and the mean BMI for all 23 patients
was 32 kg/m2, compared to only 29 kg/m2 in our study. In
addition, Miroslawka et al. found an insignificant decrease
in EGP, whereas we found an insignificant decrease in EGP
both during the basal and the clamp period 6 months after
RDN, compatible with a modest improvement in hepatic
insulin sensitivity. This is supported by a recent study, in
which it was found that in a nonhypertensive obese canine
model, RDN completely normalized hepatic insulin sensitiv-
ity (EGP), assessed by the HEC, in high-fat diet-fed animals,
compared to sham animals. The authors accordingly sug-
gested that the renal nerves play a role in the regulation of
insulin action specifically as regards EGP [22]. In our study,
glucose oxidation also decreased significantly during the
clamp period after RDN whereas lipid oxidation concur-
rently increased the borderline significantly, possibly as a
result of a lower EGP after RDN.
In parallel with the Symplicity HTN-2 trial [4], we found
a significant decrease in office-based blood pressure measure-
ments after RDN. However, the decrease in blood pressure
could relate to inadequacies of the study design, as subse-
quent more rigorously designed clinical trials using a sham
procedure and ABPM have failed to demonstrate a BP-
lowering effect [5, 6, 9]. In the current study, it is plausible
that systolic office blood pressure falls significantly as the
subjects are more used to the procedures on the second day
of examination. Therefore, the 24-hour ambulatory blood
pressure measurements are much more valid.
Hypertension is associated with the infiltration of T
cells into the kidney and vasculature, with the release of
cytokines, including IFN-γ and TNF-α, which promote
sodium retention, vasoconstriction, and oxidative injury
[7]. Obesity causes lipid accumulation in adipocytes that
can increase the production of proinflammatory cytokines
such as TNF-α, IL-6, and IL-1β, and this obesity-associated
chronic low-grade inflammation leads to insulin resistance
[23]. Moreover, increased levels of inflammatory markers
such as CRP and white cell blood count correlate with inci-
dent type 2 diabetes [8]. In our study, we could not demon-
strate an improvement in inflammatory markers 6 months
after RDN; it should however be noted that the levels of some
cytokines before RDN were below detection limit, making
detection of any change analytically problematic.
One of the limitations of the study is the small sample
size, although 8 subjects should suffice for fulfilling the
purpose of the study. Power calculations were based on the
primary endpoint, namely, theM-values found in the hyper-
insulinemic euglycemic clamp. Clamp studies are labour
intensive and technically demanding and are therefore most
commonly conducted in a restricted number of subjects,
often including around 8–10 subjects. Moreover, the method
had only been applied to 2 subjects treated with RDN [24]
when our study was designed, and therefore, there was no
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Figure 2: Correlation between BMI at 6 months after RDN and the
difference in M-value before RDN and 6 months after RDN.
R = 0 75; p = 0 03.
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precedent that allowed us to compare our results or power
calculations with those of other studies. Later, Miroslawka
et al. [21] published a study including 23 subjects with
treatment-resistant hypertension who were examined by
an HEC before and 6 months after RDN. However, as
mentioned previously, most of the participants in the
study suffered from the metabolic syndrome and were
more obese than the participants in our study.
Another limitation is that we used the unipolar Sympli-
city Flex catheter and not a multipolar catheter in our study.
Accordingly, we cannot exclude that the failure of RDN to
improve insulin resistance in all 8 subjects is due to insuffi-
cient ablation or recurrence due to nerve regeneration after
6 months.
Using an open-labelled study design, the significant
reduction in blood pressure and the partial improvement
in insulin sensitivity could be explained by the positive
“placebo” effects of being included in a study, potentially
leading to a greater awareness of a healthier lifestyle and a
better compliance to medication. The observed reductions
in blood pressure should therefore be interpreted cautiously
as previously mentioned.
Another point of criticism could also be that both males
and females were included in the study. However, as we only
included postmenopausal women, we considered them to be
comparable to the men in our study group. Moreover, we
performed a subanalysis only including the men, and the data
on the most important outcomes (M-value and blood pres-
sure) only showed a significant change in office diastolic
blood pressure, but as 24-hour ambulatory blood pressure
measurements are more precise, we do not find the change
highly relevant.
On the other hand, our study design also has strengths.
One single, highly skilled, and experienced invasive cardiolo-
gist performed the RDN, potentially increasing the rate of
success. In addition, to assess insulin sensitivity, we used
the gold standard method, HEC, and to assess hepatic insulin
sensitivity, we used a glucose tracer. Until recently, all studies
focusing on the effects of RDN on glucose metabolism have
used less suited measures like HOMA to assess insulin sen-
sitivity. Thus, in the study by Mahfoud et al., 50 patients
with treatment-resistant hypertension were included in a
study where 37 patients underwent RDN and 13 patients
comprised a control group. Forty percent of the partici-
pants had type 2 diabetes before inclusion in the study.
Fasting glucose, insulin, C-peptide levels, and insulin
resistance assessed by HOMA-IR decreased significantly 3
months after RDN, whereas there were no significant
changes in the control group [25]. In the DREAMS study
by Verloop et al., 29 patients with the metabolic syndrome
were treated with RDN. Insulin sensitivity was assessed by
the simple index assessing insulin sensitivity through the oral
glucose tolerance test and did not change 6 and 12 months
after RDN [26].
Also, in the studies just mentioned, most of the partici-
pants had diabetes or prediabetes, making the study groups
more heterogeneous compared to subjects in our study.
To our knowledge, no other study has assessed the
effects of RDN on inflammatory markers, a parameter that
could be a contributor to the association between hyper-
tension and insulin resistance. In addition, the finding that
RDN may improve insulin sensitivity in leaner subjects is
also of novelty.
5. Conclusions
In this relatively small, nonrandomized study, using gold
standard methods to assess insulin sensitivity, there were
no significant changes in basal and insulin-stimulated glu-
cose disposal and EGP after RDN. We did however find
an overall trend towards improved insulin sensitivity
largely driven by more pronounced changes in leaner sub-
jects, suggesting that RDN may be specifically beneficial in
this subgroup.
Ideally, reducing sympathetic tone by RDN could
improve both blood pressure and insulin sensitivity, thus tar-
geting two important risk factors of cardiovascular disease.
Currently, the challenge lies in identifying subgroups that
could benefit from RDN. For now, there is not enough evi-
dence to expand the indication for RDN to include insulin
resistance, as further and larger studies are needed.
6. Limitations
The most important limitation of the current study is the
small sample size, but as previously mentioned, there was
no precedent that allowed us to compare our results or power
calculations with those of other studies when our study was
designed. Power calculations were based on the primary end-
point, the M-values found in the hyperinsulinemic euglyce-
mic clamp. The SD of the M-value has been shown to be
10% in previous studies in our laboratory, and λ is the
Table 4: Blood pressure measurements.
Baseline 6 months after RDN p value
Office systolic blood pressure (mmHg) 180.4± 6.79 164.8± 8.06 0.01
Office diastolic blood pressure (mmHg) 94.88± 4.72 87.88± 3.63 0.04
Daytime ABPM systolic (mmHg) 158.3± 4.72 154.4± 5.53 0.49
Daytime ABPM diastolic (mmHg) 89.43± 2.84 88.29± 4.32 0.74
Nighttime ABPM systolic (mmHg) 151.3± 5.78 138.1± 8.00 0.06
Nighttime ABPM diastolic (mmHg) 83.71± 2.80 75.57± 4.64 0.03
All data are presented as means with SE or median (range). ABMP: 24-hour blood pressure measurements (n = 7).
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difference that we wished to detect, in this case 14%. The
power calculation was therefore N=2 × 7.9 × (10/14)2 = 8.
Consequently, eight patients would be required to dem-
onstrate a significant difference at 80% power and 5%
significance.
Another important limitation of the study is the fact that
we included both men and postmenopausal women in our
study, but as described in the study by Wassertheil-Smoller
et al. [27], women aged <55 years tend to have lower preva-
lence rates of hypertension, compared with men, but women
aged 55 to 74 years have similar rates. The women in our
study were aged between 55 and 74, making them compara-
ble to the men in our study group. We, however, performed
subanalyses only including the men, but the results did over-
all not change significantly. We therefore decided to pool
male and female patients in order to get a larger “n.”
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